



A REVIEW: NANOEMULSION BASED FORMULATION ACCEPTABLE FOR OPHTHALMIC APPLICATION

Satendra Singh Yadav* and Dr. Prerna Chaturvedi²

¹Research Scholar, Faculty of Pharmacy, Oriental University Indore.

²Associate Professor, Faculty of Pharmacy, Oriental University Indore.

***Corresponding Author: Satendra Singh Yadav**

Research Scholar, Faculty of Pharmacy, Oriental University Indore.

Article Received on 13/04/2022

Article Revised on 03/05/2022

Article Accepted on 24/05/2022

ABSTRACT

Due to the astonishing capacity for prescriptions to penetrate into the major circulatory framework, as well as the restrictions of the visual hindrances, the eye gives a few open doors and issues to sedate organization. Determinations shift contingent upon whether the objective segment of the eye is foremost or back. Nanoemulsions are a sort of fluid in-fluid scattering with beads as little as 100 nanometers. Different precorneal, dynamic, and static visual obstructions limit drug conveyance to the designated visual tissues. They have an unmistakable appearance, a high bioavailability rate, and a more extended time span of usability. Oil, water, surfactant, and cosurfactant are the fundamental parts of nanoemulsions, which might be made utilizing both high- and low-energy methods. Due to their ability to enter the profound layers of the visual construction, offer a delayed delivering impact, and limit the recurrence of organization and unfavorable impacts, weakened nanoemulsions are utilized to manage ophthalmic drugs. These most recent purposes have required examination into nano-emulsion readiness advancement draws near. We desire to frame the advancement of natural and inorganic nanoparticles for ophthalmic applications in this review. We underscore the capability of nanoemulsion in clinical investigations as well as economically accessible products.

INTRODUCTION

The eye is a touchy organ that has its own life systems and physiology. The two primary parts of the eye structure are the foremost and back sections. The front piece of the eye involves around 33% of the space, while the back section possesses the excess region. The cornea, conjunctiva, watery liquid, iris, ciliary body, and focal point are tissues found in the front piece of the eye. The back locale of the eye is involved the sclera, choroid, retinal color epithelium, brain retina, optic nerve, and glassy humor. The foremost and back segments of the eye are impacted by a few vision-undermining infections. The foremost region is impacted by messes including as glaucoma, hypersensitive conjunctivitis, front uveitis, and waterfall. The most incessant infections that influence the human body. Age-related macular degeneration (AMD) and diabetic retinopathy are the most successive sicknesses that harm the rear of the eye. Age-related macular degeneration (AMD) and diabetic retinopathy are the most continuous sicknesses that harm the rear of the eye.^[1,2]

The eye is a fragile organ, and its bended plan, compartmental design, impermeable epithelium, tear discharge, and visual waste channels shield it from unfamiliar materials.^[3-5] Traditional medication conveyance strategies, for example, eye drops,

suspensions, and salves are regularly used to treat visual ailments, however they have huge downsides. New procedures, for example, nano/microparticles, nanosuspension, nano/microemulsion, liposomes, nanomicelles, and dendrimers, then again, might have the option to defeat the previously mentioned inadequacies of customary systems.^[6] However, concentrating on visual pharmacokinetics models is quite possibly the main strategies for creating imaginative visual conveyance strategy. Pharmacokinetics studies are utilized to research the time and fixation connections of meds that have been conveyed.^[7]

Conventional Ocular Drug Delivery Systems

A patient-accommodating and regularly suggested type of medicine conveyance is effective drop instillation into the lower precorneal locale. Be that as it may, on the grounds that to visit squinting, most of the topically applied measurement is lost, with simply 20% (7 L) of the embedded portion staying in the precorneal pocket.^[8] The precorneal drug fixation capacities as a driving element for detached drug dissemination over the cornea. Nonetheless, huge corneal entrance and broadened drug cornea contact time are important for powerful visual medicine organization utilizing eye drops. There have been a few endeavors to improve precorneal home term and corneal infiltration. Iontophoresis, prodrugs, particle

pair shaping specialists, and cyclodextrins are utilized to increment corneal permeability.^[9-13] There is a huge choice of ophthalmic drugs available, with customary eye drops representing more than 70% of remedies. The causes could incorporate the straightforwardness of large scale manufacturing, high persistent acknowledgment, drug item execution, solidness, and cost effectiveness.^[14,15]

• Topical liquid/solution eye drops

Eye drop plans have various elements that make them a normally suggested structure. They are painless, safe, produce fast results after application, have great patient consistence, and are great for the item. The utilization of eye drops is described by pulsatile infiltration of the upheld drug upon skin instillation of the drops, with resulting fast downfall of the medication fixation following a motor profile that intently compares to a first request disposal process. Therefore, different modifiers, for example, cyclodextrins, thickness and penetrability enhancers, are sufficiently intense to be utilized in eye drop definitions to expand the time of medication contact, the limit of entrance, and the basic bioavailability of the objective molecule(s).^[16,17,18,19]

• Emulsions

The bioavailability and dissolvability of embodied meds are both critical to details having an emulsion character. Oil-in-water (O/W) and water-in-oil (W/O) emulsions are the essential formulative systems used to make this plan. The O/W emulsion is liked over the W/O emulsion for drug organization to visual tissues, attributable to advantages, for example, less aggravation in target tissues and further developed eye resilience to O/W emulsions.^[20,21] AzaSite, Refresh Endura, and RestasisTM are a few instances of presently promoted drugs in view of emulsion innovation.^[22-24] Countless logical examinations have had the option to affirm the advantages of utilizing emulsions, for example, expanded time of home in precorneal tissues, more noteworthy medication penetrability in corneal tissues, and the capacity to keep up with drug discharge, consequently expanding drug bioavailability.

• Suspensions

These drug structures are artificially portrayed as medication scatterings made with a hydrophilic dissolvable including a scattering specialist or a suspension, bringing about an immersed last arrangement. Moreover, when this kind of detailing doesn't need a meddlesome application procedure, it will be appropriate. The precorneal tissue assimilates the particles in the suspension, expanding how much time the prescription is in contact with the tissues and how much time the medication is remedially dynamic. One of these frameworks' idiosyncrasies is the prerequisite for very much planned molecule sizes in the definition, since this boundary straightforwardly influences the span of the remedial activity.^[25,26] The drugs dexamethasone and

tobramycin showed higher focus levels in the hare creature model utilizing the TobraDex plan.

• Ointments

Balms are likewise used as prescription conveyance strategies and are remembered for the classification of effective arrangements. Since these frameworks are comprised of a blend of strong and semisolid hydrocarbon particles, their dissolving temperatures are generally near the visual temperature of 34 C. Yet, for a specific reason, which hydrocarbon would it be advisable for us to pick? This little detail has a major effect in a definition's biocompatibility, in light of the fact that the substance should not be dismissed by the body to stay away from additional natural aftereffects and even to ensure the plan's adequacy in expanding drug bioavailability and supporting the conveyance process.^[27-30] The anti-infection vancomycin contains glycopeptides in its spine, which have shown extraordinary movement against the impacts of vigorous and anaerobic microorganisms that stain positive by the Gram strategy, as well as *Staphylococcus aureus*, which is impervious to anti-infection agents like methicillin and cephem.^[31] Regardless of this outstanding helpful effect, barely any, effective arrangements were economically open.^[32]

Novel Ocular Drug Delivery System

• Nanotechnology based ocular drug delivery

As far as helpful headways for visual ailments, the past couple of many years of logical exploration have been especially productive. The ongoing strategies in the treatment of both the foremost and back areas of the eye are the consequence of the ascent of nanotechnology in mix with deeply grounded drug drugs. Nanoparticulated frameworks with right adjusting may bring about diminished aftereffects, expanded bioavailability, and further developed ingestion limit. Nanocarriers are utilized in an assortment of courses in current practice: Dendrimers, liposomes, nanoparticles, nanosuspensions, and nanomicelles are only a couple of instances of the deadly implement accessible for treating obsessive issues in the eyes, with a considerable lot of these materials showing promising outcomes.^[34,35]

• Nanomicelles

Nanomicelles have hydrophilic polar heads outwardly and a hydrophobic greasy acyl chain within, permitting them to convey inadequately water-dissolvable prescriptions and safeguard particles like proteins and peptides. Such designs are amphiphilic, and they can be polymers or surfactants naturally.^[35,36] Cholkar et al. distributed another survey concentrate on that uncovered the fundamental limits in the utilization of these frameworks for the conveyance of prescriptions for the treatment of visual tissues. The essential advantages of this kind of plan are their simplicity of readiness, a definitive small size they produce, and their huge ability to epitomize a lot of drugs. Subsequently, definitions with this morphology empower for upgraded bioavailability of drugs to be conveyed, bringing about

better restorative results.^[37,38] The detailing organization of nanomicelles was utilized in a few clinical examinations with different drugs.

• Nanoparticles

Artificially, the nanoparticulate frameworks are colloidal carriers with sizes going from 10 nm to 1000 nm. These game plans required extraordinary syntheses to guarantee wellbeing and viability when utilized in visual tissues: Polymers got from engineered or regular sources, for example, chitosan, egg whites, sodium alginate, polylactic corrosive (PLA), poly(lactide-co-glycolide) (PLGA), or polycaprolactone, were utilized. Nanoparticle-exemplifying prescriptions can likewise be grouped into two kinds: nanocapsules and nanospheres. The prescription is epitomized in within the polymeric grid in the first. The prescription is consistently spread across the polymeric cross section in the subsequent strategy. A few exploration bunches have been keen on creating nanoparticulated custom-made structures to pass prescriptions on to foremost and back visual tissues as of late definitively.^[39,40]

• Nanosuspensions

Surfactants or polymers are utilized in these definitions to balance out the submicron-sized particles framed by medications, which then, at that point, structure colloidal scatterings. This strategy functions admirably for typifying hydrophobic drugs. When contrasted with other normal ophthalmic items, applying such a plan to the visual course of conveyance yields ideal outcomes — less bothering, a superior profile as eye drops, expanded half-life time in the precorneal tissue, disinfection of the item, and further developed ability to solubilize hydrophobic medications in the lacrimal fluid.^[41,42] A portion of these impacts were additionally investigated in nanosuspensions for visual purposes to improve glucocorticoid solubilization. The glucocorticoids dexamethasone, hydrocortisone, and prednisone are the favored meds to treat neurotic circumstances in which a differing level of irritation is available, upsetting the front part of the visual tissues. These days, a treatment plan utilizes rehashed high doses of before pharmacological medications, with waterfall, optic nerve harm, and even glaucoma creating as undesirable aftereffects. To help the visual bioavailability of the expressed prescriptions, glucocorticoids were integrated as nanosuspensions.^[43,44]

• Liposomes

Lipid vesicles are coordinated on a solitary or numerous phospholipid bilayer plan with a hydrophilic focus in these frameworks. Liposomal frameworks are described by their size and phospholipid bilayers. Thus, they are named minuscule unilamellar, with sizes going from 10 nm to 100 nm, enormous unilamellar, with sizes going from 100 nm to 300 nm, and multilamellar, with sizes more than 300 nm.^[45,46] Because of its extraordinary adequacy in typifying both hydrophilic and lipophilic meds, fantastic biocompatibility, and a shape practically

identical to the regular cell layer, liposomes are portrayed as fitting frameworks to convey drug content by means of the visual course. As indicated by different logical exploration^[47,48], liposome plans were sufficiently exact to ship their items toward the front and back pieces of the eye productively. Natarajan and associates directed another exploration on the conveyance of latanoprost typified in liposomes and managed in the front region of the visual globe, which showed the capacity to bring down intraocular strain in a bunny's eye over a time of 50 days.

• Dendrimers

Dendrimers have a star-molded polymeric web with various spreading nanoscale branches. Dendrimers can be made with an assortment of changes to the chain terminals, including the presence of a few practical gatherings like amine, carboxyl, or hydroxyl gatherings. They additionally arrive in a wide range of atomic loads. With the capacity to wear on unique synthetic gatherings comes the chance of particular formation with different particles in view of the ideal climate. To make a framework reasonable for drug conveyance, these frameworks should have their fundamental elements improved, like practical gatherings, particle calculation, surface charge, and sub-atomic weight. Lipophilic or hydrophilic drugs can be encased thanks to the surprising construction of dendrimers.^[49–50]

• In-situ gelling systems

The term alludes to a polymeric arrangement that might go through a stage progress among arrangement and gel, in the end making a gel with viscoelastic properties because of contributions from the climate. Different elements that cause gelation incorporate pH changes, temperature, the presence or nonappearance of particles, and UV radiation openness. The temperature was picked as the essential part in the turn of events and utilization of a framework like this in the visual construction.^[51,52] The distributed writing depicts a wide scope of polymers that are delicate to temperature changes and can be utilized in the eyes.

Ocular barriers

Physical and physiological limits recognize visual designs. Following skin treatment, the prescription is retained either through the corneal or non-corneal pathways.^[53] To acquire a powerful focus in the retina and glassy, prescriptions directed locally or foundationally should conquer these hindrances. The blood-visual hindrance (BOB) is accountable for directing the liquid structure and watery humor, as well as controlling the info and outpouring of fluid humor, permitting the eye to keep up with ideal tension. Physiological and physical hindrances to visual medicine organization have been identified. Physiological boundaries incorporate

1. Tear turnover
2. Naso-lachrymal drainage
3. Blinking.

Static and dynamic physical boundaries are utilized to keep drugs from entering the foremost segment. The corneal epithelium, stroma, and blood-watery hindrance (BAB) structure the static obstruction, while dynamic boundaries control conjunctival blood and lymph stream, as well as tear waste. Tight associations of the ciliary body's non-pigmented epithelium, iridial tissue intersections, and iris veins make up the BAB. The mix of these factors keeps drugs from entering the foremost office of the eye. The sclera, Bruch's layer choroid (BC), retinal shade epithelium (RPE), and conjunctiva are static hindrances in the back fragment, though powerful boundaries are associated with drug leeway through blood and lymphatic conduits. The BOB, which contains tight associations in retinal fine endothelial cells and RPE cells, is generally comprised of the BAB and the blood-retinal hindrance (BRB), which restricts the accessibility of helpful medications in visual compartments. Through iris-ciliary vessels, the BAB limits atomic vehicle from blood to fluid humor.^[54,55] Mucin, a gel-like substance that plays a defensive part in the eye, is one more impediment to visual conveyance. On the corneal and conjunctival surfaces of the eye, mucin structures boundary layers. Mucin is likewise remembered to go about as a pervasion hindrance, restricting visual drug ingestion, despite the fact that there is no obvious evidence that it does as such. The mucin layer might forestall huge atom medications from diffusing. It isn't clear which job the mucin hindrance plays in medicine retention. Moreover, efflux siphons communicated on the hairlike endothelium, like P-glycoprotein (P-gp), multidrug obstruction protein (MRP), and bosom disease opposition protein (BCRP), address a critical hindrance to medicine assimilation.^[56]

Composition of The Nanoemulsions Administered To The Eye

As a rule, ophthalmic o/w nanoemulsions are scatterings of slick drops in a watery climate. Therefore, these plans require cautious thought of the sleek stage's arrangement (i.e., the utilization of nontoxic, nonirritating, chemically approved oils) as well as the watery medium's organization. The need for isotonicity of the visual nanoemulsions, the fundamental pH, a specific buffering limit, the incorporation of additives (antimicrobial specialists), thickness modifiers, and cell reinforcements, like that of ophthalmic drops, requires cautious thought. Moreover, a careful change of the organization as well as the grouping of surfactants and cosurfactants in the definition is important to make nanosize homogeneous beads of oils. The unpredictability of ophthalmic nanoemulsion organizations requires broad information and mastery in drug plans to create steady, drug level arrangements. The most frequently utilized parts of ophthalmic nanoemulsions, including as oils, emulsifiers, surfactants, and cosurfactants, as well as added substances used to upgrade their therapeutic characteristics, are portrayed inside and out in this segment (e.g., constitution, thickness, or pH of the definition).^[57,58]

Oil Phase

The scattered stage in ophthalmic nanoemulsions goes from 5 to 20 weight percent oil/lipid. The solvency of API in different oils is broadly used to pick the oil stage for nanoemulsion plan. Furthermore, the oil utilized in the detailing should be all around endured and viable with the other nanoemulsion excipients. Triacetin and vitamin E are additionally expressed as parts in the nanoemulsion controlled to the eye, and these two synthetic compounds can work as humectants and cell reinforcements in ophthalmic definitions. Besides, a mix of oils can be utilized to produce clear details with lower scattering stage thickness (a model incorporates the blend of castor oil with medium chain fatty substances in 1:1 proportion, bringing about an abatement of castor oil consistency).^[59,60,61,62]

Surfactants and Cosurfactants

Surfactants and cosurfactants are key parts of nanoemulsions that change their actual steadiness and consider viable emulsification of the oil into the consistent stage. The surfactant ought to be dissolvable in the nanoemulsion's constant stage, have an extremely low interfacial pressure, and restrain oil drop blend during homogenization. The eye drops contain amphoteric emulsifiers like soybean or chicken egg lecithin and its portions, as well as amphoteric surfactants (e.g., Miranol MHT and Miranol C2M conc NP).^[63,64] The incorporation of amphiphilic synthetics, otherwise called cosurfactants, might be important to work on the miscibility of the two stages and guarantee interface smoothness. Short-and medium-chain alcohols (e.g., ethanol, benzyl liquor, and so forth) are the most frequently utilized cosurfactants in visual nanoemulsions.

Water Phase

The nanoemulsion's droplet size and stability may be affected by the water phase's composition. The pH value and the presence of electrolytes and ions should be checked while making nanoemulsions since they can alter the size of the dispersed phase and the formulation's stability.^[65,66] Pharmacopoeial water for injections or buffered saline solution are the most widely utilised water phases in ocular medicines.

Other Auxiliary Substances

To empower for application to the eyeball, ophthalmic details should incorporate additives, supports, osmotic tension, thickness modifiers, humectants, or gelling specialists. Additives in visual nanoemulsions incorporate benzalkonium chloride (0.010.1% w/v), cetrimide (0.010.1% w/v), chlorocresol, parabens, and alcohols (e.g., chlorobutanol and phenoxy-2-ethanol).^{34,38} If buffering is important, citrate, phosphate, or borate cradles are used.^[67]

The osmotic strain of visual nanoemulsions is adjusted utilizing mannitol (0.150.3 percent w/v), glycerol (2.55 percent w/v), sorbitol, propylene glycol, and dextrose. To

improve the consistency of visual nanoemulsions, normal and manufactured polymers with solid water-engrossing properties can be added, bringing about viscoelastic gels. Accordingly, the medication can keep in contact with the cornea for longer, maybe working on its bioavailability. This should be possible with polysaccharide polymers like methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, gellan gum, thickener, and hyaluronic corrosive, as well as engineered polymers like poly(vinyl liquor), polyvinylpyrrolidone, carbomeric (pitifully all amic corrosive), and polyethylene glyceric corrosive.^[68,69]

Nanoemulsions

A straightforward and stable scattering of oil and water is named a nanoemulsion. Interior, scattered, and outside stages, as well as the scattering medium, make up most of them. In light of their capacity to lessen interfacial strain and make little molecule sizes because of their capacity in the arrangement of stable arrangements because of terrible electrostatic communication and steric impediment, surfactant and cosurfactant particles assume a significant part in the development of nanoemulsions. Surfactants are particles with a bipolar construction that incorporates both hydrophilic and hydrophobic regions.^[70]


Nanoemulsions are colloidal medication transporters with bead sizes going from 500 to 1000 nanometers (ideally from 100 nm to 500 nm). As a drug conveyance system, they work on remedial viability while decreasing incidental effects and hurtful reactions from the medication.^[71]

Advantages of nanoemulsions

As a result of their enormous surface region and minuscule bead size, nanoemulsions increment prescription bioavailability, are non-aggravation, non-poisonous, and genuinely steady, and advance medication assimilation. Nanoemulsions may likewise be made in an assortment of ways, break up lipophilic drugs, utilize less energy, and disguise upsetting preferences. Nanoemulsions have disadvantages.^[72] Nanoemulsions require a great deal of surfactants and cosurfactants to keep them stable, and they just have a restricted capacity to break down high-dissolving point compounds. Furthermore, surfactant harmfulness should be tended to, and numerous natural variables could influence nanoemulsion soundness. The advantages and downsides of nanoemulsions, as well as a portion of their actual elements, are summed up.^[73]

Formulation of ophthalmic nanoemulsions

The researcher devises a number of strategies for creating a nanoemulsion. As previously said, there are two types of methods: high and low energy.



Evaluation of Ophthalmic Nanoemulsion (Parameters For Evaluation)

Zeta potential

The estimation of charge aversion among oil nanodroplets is known as zeta potential. This is quite possibly the most essential component affecting the solidness of a circulated framework. A nanoemulsion with a high zeta potential is steady. The distinction in electrical potential between the scattering medium and the fixed layer of liquid close to the scattered oil nanodroplets decides its worth. 50,54 The ideal zeta potential territory is somewhere in the range of +20 and +40 millivolts.^[75,76]

Refractive index

Refractometer might be utilized to decide the refractive file. This action is utilized to survey any expected visual hindrance or distress following the conveyance of an eye drop.^[77] Tear liquid has a refractive record of 1.340 to 1.360. The refractive record of eye drops should be under 1.476. 56 Transmittance rate A spectrophotometer set to a given frequency and refined water as a clear can be utilized to work out the % conveyance. In the event that the rate conveyance of the shaped nanoemulsion is more prominent than close to 100%, it is considered straightforward.^[78]

pH

A pH meter might be utilized to decide the pH of nanoemulsions, which ought to be around 7.20.2 for best solace. Whenever the pH of the imparted arrangement

contrasts from that of the tear, it causes distress and aggravation, which is reliant upon how much time the arrangement is in touch with the eye surface, the arrangement synthesis, the volume ingrained, and the buffering limit. In any case, on the grounds that the tear pH might be changed to physiological qualities, a nanoemulsion with an alternate pH can be endured much of the time when the readiness is neither cradled or gently cushioned.^[79,80]

Surface tension

At the point when the surface strain of eye drops is a lot of lower than that of the lachrymal liquid (40-50 mN/m), the tear film is obliterated.^[81] Rheological investigation The effect of an ophthalmic readiness on ordinary tear conduct ought to be kept to a base; a less thick arrangement takes into account restricted flickering torment and great resistance, though a more gooey one can further develop the medication's home time and visual bioavailability; eye drops ought to have a consistency of something like 20 mPas.^[82]

Osmolality

The osmolality of lacrimal fluid ranges from 280 to 293 mOsm/kg. However, evaporation reduces the osmolality to between 231-446 mOsm/kg when the eye is opened. The preparation will irritate the eye if the osmolality of the solution is less than 100 or higher than 640 mOsm/kg. However, 1-2 minutes after injecting a non-isotonic fluid, the osmolality is restored.^[83]

Ocular irritation study

These tests should guarantee that corneal structure and integrity are not compromised.^[84]

CONCLUSION

Nanoemulsions are believed to be the most encouraging technique for further developing visual prescription conveyance. Planning ophthalmic nanoemulsions requires a careful handle of both drug and specialized parts of excipient determination and definition systems. This Review tries to give perusers a total outline of nanoemulsion piece choices. Quite possibly the most captivating and complex undertaking confronting drug researchers is ophthalmic prescription conveyance. The request has been utilized for a long time by connecting nanotechnology to novel transporters, for example, polymeric and lipid nanoparticles, microspheres, niosomes, liposomes, etc. Albeit these nanocarriers work on visual ingestion when contrasted with customary treatment techniques, they have a few disadvantages that Nanoemulsion doesn't. Nanoemulsions are fitting for building a skin visual conveyance framework since they can give delayed drug discharge examples and patient consistence. Ophthalmic visual suspensions and arrangements have low bioavailability and need rehashed measurements, but NEs offer colossal potential for improving bioavailability and decreasing medication instillation recurrence to increment patient consistence and biocompatibility.

Future Scope

Conceivable future Despite expansive investigation in the field of NEs for visual use, only couple of them have progressed to clinical primers in view of a couple of obstacles experienced during the improvement stage, as physicochemical assessment, hurtfulness examination, quality control, in-vitro testing, ailing in-vivo animal focus on models, and upgrade of a couple of specifying headway limits. The goal of the survey is to target issues in the back area of the eye using a kept up with/controlled release system, NEs with high prescription stacking that could replace meddling courses like intravitreal implantations and transscleral and uveal courses. The continuously extending and developing people ought to similarly be thought of. In addition, future assessment should zero in on making plans with lessened hurtfulness profiles and further created medication ingestion in the eye's ongoing situation. Diminished portion repeat, further created drug zeroing in on, higher bioavailability, and prosperity through skin course are issues that ought to be tended to. Animal or in vitro cell line models are significant for ophthalmic definition appraisal at all times of investigation, however their worth in human models should be tended to as a result of differences in remarkable visual deterrents like squinting among people and animals.

Conflicts of Interest

The author declares that there are no conflicts of interest.

Funding

Nil.

ACKNOWLEDGEMENT

I am thankful to the management of Department for providing best lab facilities necessary for completion of my research.

REFERENCES

1. Boursals CL, Acar L, Zia H, Sado PA, Needham T, Leverage R. Ophthalmic drug delivery systems recent advances. *Prog Retin Eye Res.*, 1998; 17: 33–58. 10.1016/S1350-9462(97)00002-5.
2. Gulsen D, Chauhan A. Ophthalmic drug delivery through contact lenses. *Invest Ophthalmol Vis Sci.*, 2004; 45: 2342–2347. 10.1167/iovs.03-0959.
3. Worakul N, Robinson JR. Ocular pharmacokinetics/pharmacodynamics. *Eur J Pharm Biopharm*, 1997; 44(1): 71–83.
4. McGhee PCN. An overview of topical ophthalmic drugs and the therapeutics of ocular infection. *CNJ McGhee: Ocular Therapeutics*.
5. Sharma PK, Banik A, Dixit SJ. A new trend: ocular drug delivery system. *Pharma Science Monitor*, 2011; 2(3): 1–25.
6. Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: an overview. *World journal of pharmacology*, 2013; 2(2): 47–64.

7. Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. *Adv Drug Deliv Rev.*, 2006; 58(11): 1131–5.
8. Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. *AAPS J.*, 2010; 12(3): 348–60.
9. Khurana V, Kwatra D, Agrahari V. Recent advances in ocular, drug delivery. *Adv Drug Deliv*, 2014; (Chapter 19).
10. Barar J, Asadi M, Mortazavi-Tabatabaei SA, Omid Y. Ocular drug delivery; impact of in vitro cell culture models. *Journal of ophthalmic & vision research*, 2009; 4(4): 238–52.
11. Achouri D, Alhanout K, Piccerelle P, Andrieu V. Recent advances in ocular drug delivery. *Drug Dev Ind Pharm*, 2013; 39(11): 1599–617.
12. Barar J, Javadzadeh AR, Omid Y. Ocular novel drug delivery: impacts of membranes and barriers. *Expert opinion on drug delivery*, 2008; 5(5): 567–81.
13. Ghate D, Edelhauser HF. Ocular drug delivery. *Expert opinion on drug delivery*, 2006; 3(2): 275–87.
14. Ruponen M, Urtti A. Undefined role of mucus as a barrier in ocular drug delivery. *Eur J Pharm Biopharm*, 2015; 96: 442–6.
15. Gaudana R, Jwala J, Boddu SH, Mitra AK. Recent perspectives in ocular drug delivery. *Pharm Res.*, 2009; 26(5): 1197–216.
16. Gaudana, R.; Ananthula, H.K.; Parenky, A.; Mitra, A.K. Ocular Drug Delivery. *AAPS J.*, 2010; 12: 348–360.
17. Tiwari, R.; Pandey, V.; Asati, S.; Soni, V.; Jain, D. Therapeutic challenges in ocular delivery of lipid based emulsion. *Egypt. J. Basic Appl. Sci.*, 2018; 5: 121–129.
18. Kuno, N.; Fujii, S. Recent Advances in Ocular Drug Delivery Systems. *Polymers*, 2011; 3: 193–221.
19. Lavik, E.; Kuehn, M.H.; Kwon, Y.H. Novel drug delivery systems for glaucoma. *Eye* 2011, 25, 578.
20. Peng, C.C.; Bengani, L.C.; Jung, H.J.; Leclerc, J.; Gupta, C.; Chauhan, A. Emulsions and microemulsions for ocular drug delivery. *J. Drug Deliv. Sci. Technol*, 2011; 21: 111–121.
21. Tamilvanan, S.; Benita, S. The potential of lipid emulsion for ocular delivery of lipophilic drugs. *Eur. J. Pharm. Biopharm*, 2004; 58: 357–368.
22. Opitz, D.L.; Harthan, J.S. Review of Azithromycin Ophthalmic 1% Solution (AzaSite®) for the Treatment of Ocular Infections. *Ophthalmol. Eye Dis.*, 2012; 4: 1–14.
23. Ousler, G.W.; Michaelson, C.; Christensen, M.T. An evaluation of tear film breakup time extension and ocular protection index scores among three marketed lubricant eye drops. *Cornea*, 2007; 26: 949–952.
24. Ursea, R.; Purcell, T.L.; Tan, B.U.; Nalgirkar, A.; Lovaton, M.E.; Ehrenhaus, M.R.; Schanzlin, D.J. The effect of cyclosporine A (Restasis) on recovery of visual acuity following LASIK. *J. Refract. Surg.*, 2008; 24: 473–476.
25. Yasueda, S.; Inada, K.; Matsuhisa, K.; Terayama, H.; Ohtori, A. Evaluation of ophthalmic suspensions using surface tension. *Eur. J. Pharm. Biopharm*, 2004; 57: 377–382.
26. Edman, P. Pharmaceutical formulations—Suspensions and solutions. *J. Aerosol. Med.*, 1994; 7: S3–S6.
27. Robin, J.S.; Ellis, P.P. Ophthalmic ointments. *Surv. Ophthalmol*, 1978; 22: 335–340.
28. 56. Scruggs, J.; Wallace, T.; Hanna, C. Route of absorption of drug and ointment after application to the eye. *Ann. Ophthalmol*, 1978; 10: 267–271.
29. MacKeen, D.L. Aqueous formulations and ointments. *Int. Ophthalmol. Clin.*, 1980; 20: 79–92.
30. Ditmar, M.F. CHAPTER 11—Infectious Diseases. In *Pediatric Secrets*, 5th ed.; Polin, R.A., Ditmar, M.F., Eds.; Mosby: Philadelphia, PA, USA, 2011; 354–422.
31. Ye, Z.-K.; Li, C.; Zhai, S.-D. Guidelines for Therapeutic Drug Monitoring of Vancomycin: A Systematic Review. *PLoS ONE*, 2014; 9: e99044.
32. Baranowski, P.; Karolewicz, B.; Gajda, M.; Pluta, J. Ophthalmic Drug Dosage Forms: Characterisation and Research Methods. *Sci. World J.*, 2014; 14.
33. Sultana, Y.; Maurya, D.P.; Iqbal, Z.; Aqil, M. Nanotechnology in ocular delivery: Current and future directions. *Drugs Today (Barc)*, 2011; 47: 441–455. [CrossRef]
34. Liu, S.; Jones, L.W.; Gu, F.X. Nanomaterials for Ocular Drug Delivery. *Macromol. Biosci*, 2012; 12: 608–620. [CrossRef]
35. Vadlapudi, A.D.; Mitra, A.K. Nanomicelles: An emerging platform for drug delivery to the eye. *Ther. Deliv*, 2013; 4: 1–3.
36. Trinh, H.M.; Joseph, M.; Cholkar, K.; Mitra, R.; Mitra, A.K. Nanomicelles in Diagnosis and Drug Delivery (Chapter 3). In *Emerging Nanotechnologies for Diagnostics, Drug Delivery and Medical Devices*; Mitra, A.K., Cholkar, K., Mandal, A., Eds.; Elsevier: Boston, MA, US., 2017.
37. Cholkar, K.; Patel, A.; Vadlapudi, A.D.; Mitra, A.K. Novel Nanomicellar Formulation Approaches for Anterior and Posterior Segment Ocular Drug Delivery. *Recent Pat. Nanomed*, 2012; 2: 82–95.
38. Cholkar, K.; Gilger, B.C.; Mitra, A.K. Topical, Aqueous, Clear Cyclosporine Formulation Design for Anterior and Posterior Ocular Delivery. *Transl. Vis. Sci. Technol*, 2015; 4: 1.
39. 160. Khan, I.; Saeed, K.; Khan, I. Nanoparticles: Properties, applications and toxicities. *Arabian J. Chem.*, 2017.
40. Vasconcelos, A.; Vega, E.; Pérez, Y.; Gómara, M.J.; García, M.L.; Haro, I. Conjugation of cell-penetrating peptides with poly (lactic-co-glycolic acid)-polyethylene glycol nanoparticles improves ocular drug delivery. *Int. J. Nanomed*, 2015; 10: 609–613.
41. Kassem, M.A.; Abdel Rahman, A.A.; Ghorab, M.M.; Ahmed, M.B.; Khalil, R.M. Nanosuspension as an ophthalmic delivery system for certain

- glucocorticoid drugs. *Int. J. Pharm.*, 2007; 340: 126–133.
42. Das, S.; Suresh, P.K. Nanosuspension: A new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to amphotericin B. *Nanomed. Nanotechnol. Biol. Med.*, 2011; 7: 242–247.
 43. Patel, V.R.; Agrawal, Y.K. Nanosuspension: An approach to enhance solubility of drugs. *J. Adv. Pharm. Tech. Res.*, 2011; 2: 81–87.
 44. Ahire, E.; Thakkar, S.; Darshanwad, M.; Misra, M. Parenteral nanosuspensions: A brief review from solubility enhancement to more novel and specific applications. *Acta Pharm. Sin. B.*, 2018; 8: 733–755.
 45. Heller, J.; Schacht, E.; Toncheva, V. PEG-Polyacetal and PEG-Polyacetal-POE Graft Copolymers and Pharmaceutical Compositions. U.S. Patent US20060235161, 19 October 2006.
 46. Akbarzadeh, A.; Rezaei-Sadabady, R.; Davaran, S.; Joo, S.W.; Zarghami, N.; Hanifehpour, Y.; Samiei, M.; Kouhi, M.; Nejati-Koshki, K. Liposome: Classification, preparation, and applications. *Nanoscale Res. Lett.*, 2013; 8: 102.
 47. Agarwal, R.; Iezhitsa, I.; Agarwal, P.; Abdul Nasir, N.A.; Razali, N.; Alyautdin, R.; Ismail, N.M. Liposomes in topical ophthalmic drug delivery: An update. *Drug Deliv*, 2016; 23: 1075–1091.
 48. Mishra, G.P.; Bagui, M.; Tamboli, V.; Mitra, A.K. Recent Applications of Liposomes in Ophthalmic Drug Delivery. *J. Drug Deliv.*, 2011; 1–14. [CrossRef]
 49. Abbasi, E.; Aval, S.F.; Akbarzadeh, A.; Milani, M.; Nasrabadi, H.T.; Joo, S.W.; Hanifehpour, Y.; Nejati-Koshki, K.; Pashaei-Asl, R. Dendrimers: Synthesis, applications, and properties. *Nanoscale Res. Lett.*, 2014; 9: 247.
 50. Wu, L.P.; Ficker, M.; Christensen, J.B.; Trohopoulos, P.N.; Moghimi, S.M. Dendrimers in Medicine: Therapeutic Concepts and Pharmaceutical Challenges. *Bioconjugate Chem.*, 2015; 26: 1198–1211.
 51. Sheshala, R.; Kok, Y.Y.; Ng, J.M.; Thakur, R.R.; Dua, K. In Situ Gelling Ophthalmic Drug Delivery System: An Overview and Its Applications. *Recent Pat. Drug Deliv. Formul*, 2015; 9: 237–248.
 52. Kouchak, M. In Situ Gelling Systems for Drug Delivery. *Jundishapur J. Nat. Pharm. Prod.*, 2014; 9: e20126.
 53. J.G. Cunha-Vaz, The blood-ocular barriers: past, present, and future, *Doc Ophthalmol*, 1997; 93: 149–157.
 54. M. Tomi, K. Hosoya, The role of blood-ocular barrier transporters in retinal drug disposition: an overview, *Expert Opin Drug Metab Toxicol*, 2010; 6: 1111–1124.
 55. R. Suri, S. Beg, K. Kohli, Target strategies for drug delivery bypassing ocular barriers, *Journal of Drug Delivery Science and Technology*, 2020; 55: 101389.
 56. G. Jacobs, M. Martens, J.D. Beer, Selecting Optimal Dosage Volumes for Eye Irritation Tests in The Rabbit, *Cut. & Ocular Toxicol.*, 1987; 6: 109–116.
 57. B. Srividya, R.M. Cardoza, P. Amin, Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system, *Journal of controlled release*, 2001; 73: 205–211.
 58. B. Jeong, S.W. Kim, Y.H. Bae, Thermosensitive sol–gel reversible hydrogels, *Advanced drug delivery reviews*, 64(2012): 154–162.
 59. Morsi, N. M.; Mohamed, M. I.; Refai, H.; El Sorogy, H. M. Nanoemulsion as a Novel Ophthalmic Delivery System for Acetazolamide. *Int. J. Pharm. Pharm. Sci.*, 2014; 6(11): 227–236.
 60. Weng, Y.; Liu, J.; Jin, S.; Guo, W.; Liang, X.; Hu, Z. Nanotechnology-Based Strategies for Treatment of Ocular Disease. *Acta Pharm. Sin. B.*, 2017; 7: 281–291.
 61. Nisha, S.; Deepak, K. An Insight to Ophthalmic Drug Delivery System. *Int. J. Pharm. Stud. Res.*, 2012; 3(2): 9–13.
 62. Lim, C.; Kim, D.-w.; Sim, T.; Hoang, N. H.; Lee, J. W.; Lee, E. S.; Youn, Y. S.; Oh, K. T. Preparation and Characterization of a Lutein Loading Nanoemulsion System for Ophthalmic Eye Drops. *J. Drug Delivery Sci. Technol*, 2016; 36: 168–174.
 63. Morsi, N. M.; Mohamed, M. I.; Refai, H.; El Sorogy, H. M. Nanoemulsion as a Novel Ophthalmic Delivery System for Acetazolamide. *Int. J. Pharm. Pharm. Sci.*, 2014; 6(11): 227–236.
 64. Weng, Y.; Liu, J.; Jin, S.; Guo, W.; Liang, X.; Hu, Z. Nanotechnology-Based Strategies for Treatment of Ocular Disease. *Acta Pharm. Sin. B* 2017, 7, 281–291.
 65. Qadir, A.; Faiyazuddin, M. D.; Talib Hussain, M. D.; Alshammari, T. M.; Shakeel, F. Critical Steps and Energetics Involved in a Successful Development of a Stable Nanoemulsion. *J. Mol. Liq.*, 2016; 214: 7–18.
 66. Nagariya, K.; Sharma, P. K.; Sarangdevot, Y. S. Nanoemulsion: Safe, Stable and Effective Formulation System for Ophthalmology. *Am. J. PharmTech Res.*, 2013; 3(3): 253–267.
 67. Shen, J.; Lu, G. W.; Hughes, P. Targeted Ocular Drug Delivery with Pharmacokinetic/Pharmacodynamic Considerations. *Pharm. Res.*, 2018; 35(11): 217.
 68. Shafiq-Un-Nabi, S.; Shakeel, F.; Talegaonkar, S.; Ali, J.; Baboota, S.; Ahuja, A.; Khar, R. K.; Ali, M. Formulation Development and Optimization Using Nanoemulsion Technique: A Technical Note. *AAPS PharmSciTech*, 2007; 8(2): E12.
 69. Patravale, V. B.; Date, A. A. Microemulsions: Pharmaceutical Applications. *Microemulsions*; John Wiley & Sons, Ltd: Chichester, UK, 2009; 259–301. DOI: 10.1002/9781444305524.ch9.
 70. Rajurkar, K.; Dubey, S.; Gupta, P. P.; John, D.; Chauhan, L. Compliance to Topical Anti-Glaucoma Medications among Patients at a Tertiary Hospital in

- North India. *J. Curr. Ophthalmol*, 2018; 30(2): 125-129.
71. Kholdebarin, R.; Campbell, R. J.; Jin, Y. P.; Buys, Y. M.; Beiko, G.; Birt, C.; Damji, K.; Feldman, F.; Lajaoie, C.; Kulkarni, S.; Martow, J.; Sakamoto, T.; Spencer, J.; Trope, G. E. Multicenter Study of Compliance and Drop Administration in Glaucoma. *Can. J. Ophthalmol*, 2008; 43(4): 454-461.
 72. Weng, Y.; Liu, J.; Jin, S.; Guo, W.; Liang, X.; Hu, Z. Nanotechnology-Based Strategies for Treatment of Ocular Disease. *Acta Pharm. Sin. B.*, 2017; 7: 281-291.
 73. Nisha, S.; Deepak, K. An Insight to Ophthalmic Drug Delivery System. *Int. J. Pharm. Stud. Res.*, 2012; 3(2): 9-13.
 74. Lim, C.; Kim, D.-w.; Sim, T.; Hoang, N. H.; Lee, J. W.; Lee, E. S.; Youn, Y. S.; Oh, K. T. Preparation and Characterization of a Lutein Loading Nanoemulsion System for Ophthalmic Eye Drops. *J. Drug Delivery Sci. Technol*, 2016; 36: 168-174.
 75. Daull P, Lallemand F, Garrigue JS. Benefits of cetalkonium chloride cationic oil-in-water nanoemulsions for topical ophthalmic drug delivery. *J Pharm Pharmacol*, 2014; 66: 531-541.
 76. Wu TH, Craven A, Tran T, Tran K, So K, Levi DM, Li RW. Enhancing coarse-to-fine stereo vision by perceptual learning: An asymmetric transfer across spatial frequency spectrum. *Invest Ophthalmol Vis Sci.*, 2014; 55: 751.
 77. Liu DX, Zhao XT, Liang W, Li JW. The stability and breakage of oil-in-water from polymer flooding produced water. *Pet Sci Technol*, 2013; 31: 2082-2088.
 78. Gurpreet K, Singh SK. Review of nanoemulsion formulation and characterization techniques. *Indian J Pharm Sci.*, 2018; 80: 781-789.
 79. Mahran A, Ismail S, Allam AA. Development of Triamcinolone Acetonide Loaded Microemulsion as a Prospective Ophthalmic Delivery System for Treatment of Uveitis: In Vitro and In Vivo Evaluation. *Pharmaceutics*, 2021; 13: 444.
 80. Salimi A. Preparation and evaluation of celecoxib nanoemulsion for ocular drug delivery. *Asian J Pharm.*, 2017; 11: 543-550.
 81. Mahboobian MM, Foroutan SM, Aboofazeli R. Brinzolamide-loaded nanoemulsions: in vitro release evaluation. *Iran J Pharm Sci.*, 2016; 12: 75-93.
 82. Lallemand F, Schmitt M, Bourges JL, Gurny R, Benita S, Garrigue JS. Cyclosporine a delivery to the eye: a comprehensive review of academic and industrial efforts. *Eur J Pharm Biopharm*, 2017; 117: 14-28.
 83. Sharif HR, Sharif MK, Zhong F. Preparation, characterization and rheological properties of vitamin E enriched nanoemulsion. *Pak J Food Sci.*, 2017; 27: 7-14.
 84. Gallarate M, Chirio D, Bussano R, Peira E, Battaglia L, Baratta F, Trotta M. Development of O/W nanoemulsions for ophthalmic administration of timolol. *Int J Pharm.*, 2013; 440: 126-134.